Picture of RemeGen Co logo

9995 RemeGen Co Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapSucker Stock

Momentum

Relative Strength (%)
1m+24.84%
3m-20.66%
6m-39.89%
1yr-46.96%
Volume Change (%)
10d/3m+37.07%
Price vs... (%)
52w High-51.45%
50d MA+18.24%
200d MA-22.84%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-28.47%
Return on Equity-29.08%
Operating Margin-138.23%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of RemeGen Co EPS forecast chart

Profile Summary

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    September 30th, 2023
    Incorporated
    July 4th, 2008
    Public Since
    November 9th, 2020
    No. of Shareholders
    4,475
    No. of Employees
    3,332
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    hk flag iconStock Exchange of Hong Kong Limited
    Shares in Issue
    540,255,750

    9995 Share Price Performance

    Upcoming Events for 9995

    Similar to 9995

    Picture of Abbisko Cayman logo

    Abbisko Cayman

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Akeso logo

    Akeso

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Alphamab Oncology logo

    Alphamab Oncology

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Antengene logo

    Antengene

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ascentage Pharma International logo

    Ascentage Pharma International

    hk flag iconStock Exchange of Hong Kong Limited

    FAQ